Y Intercept Hong Kong Ltd Acquires 13,698 Shares of DexCom, Inc. (NASDAQ:DXCM)

Y Intercept Hong Kong Ltd grew its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 82.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 30,282 shares of the medical device company's stock after purchasing an additional 13,698 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in DexCom were worth $2,068,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Golden State Wealth Management LLC lifted its stake in shares of DexCom by 211.2% in the first quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares during the period. Optiver Holding B.V. acquired a new position in shares of DexCom in the fourth quarter worth approximately $33,000. TD Private Client Wealth LLC lifted its stake in shares of DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after acquiring an additional 167 shares during the period. Heck Capital Advisors LLC acquired a new position in shares of DexCom in the fourth quarter worth approximately $38,000. Finally, Alpine Bank Wealth Management acquired a new position in shares of DexCom in the first quarter worth approximately $40,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction on Thursday, June 26th. The stock was sold at an average price of $85.06, for a total transaction of $124,697.96. Following the completion of the sale, the executive vice president owned 108,155 shares in the company, valued at approximately $9,199,664.30. This represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $83.13, for a total value of $228,607.50. Following the sale, the director owned 56,621 shares of the company's stock, valued at $4,706,903.73. This trade represents a 4.63% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Barclays lifted their price objective on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Citigroup reaffirmed a "buy" rating and issued a $102.00 price objective (up from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Morgan Stanley lifted their price objective on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a research note on Tuesday, July 15th. Robert W. Baird dropped their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Finally, Piper Sandler dropped their price target on DexCom from $100.00 to $90.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and a consensus target price of $99.60.

DexCom Stock Up 2.6%

Shares of NASDAQ DXCM traded up $2.25 during midday trading on Friday, hitting $88.99. 3,072,147 shares of the stock traded hands, compared to its average volume of 2,733,721. The company has a market cap of $34.89 billion, a PE ratio of 66.41, a P/E/G ratio of 1.85 and a beta of 1.44. DexCom, Inc. has a one year low of $57.52 and a one year high of $93.25. The business has a 50 day moving average price of $84.58 and a two-hundred day moving average price of $80.41. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The firm had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter in the prior year, the firm earned $0.32 EPS. The company's revenue was up 12.5% compared to the same quarter last year. On average, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.